Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease

Not Applicable

Terminated

• Conditions: Polycystic Kidney
• Interventions: Drug: Emodin; Drug: tripterygium wilfordii

• Registration Number: NCT00801268
• Lead Sponsor: Zhi-Hong Liu, M.D.

Brief Summary

Triptolide has been approve effective in animal model.

Detailed Description

Randomized

Study Timeline

• Study Start: 2008-11
• Study First Submitted: 2008-11-25
• Study First Submitted QC: 2008-12-02
• Study First Posted: 2008-12-03
• Primary Completion: 2013-11
• Study Completion: 2013-11
• Status Verified: 2015-03
• Last Update Submitted: 2015-03-27
• Last Update Posted: 2015-03-30

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Clinically established ADPKD
• eGFR>30ml/min.
• Chinese nationality

Exclusion Criteria

• Uncontrolled infections
• Non-ADPKD complications

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
emodin	Emodin	-
Triptolide Woldifii	tripterygium wilfordii	TW60mg/d

Primary Outcome Measures

Name	Time	Method
MRI calculated kidney volume, eGFR	Every 3-6months

Secondary Outcome Measures

Name	Time	Method
End-stage kidney disease (ESRD)	every 2months

Trial Locations

Locations (2)

Liu ZH, Yao XD,Chen X,Hu YL; 🇨🇳 Nanjing, Jiangsu, China

Yao Xiaodan; 🇨🇳 Nanjing, Jiangsu, China